دورة المؤشرنت للتحليل الفني
50 دينار كويتي
Immu
- بادئ الموضوع real man
- تاريخ البدء
al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
اختي السهم استثماري ولاخوف عليه في الوقت الحاضر ان شاء الله
قلعتي استاهل اللي يصيرلي
الطمع شين
ترا خانقتني العبرة وأبي أبجي
الشركة:- اخبارها ممتازة الان وفي المستقبل
موريس يَتأسّى، إن. جْي . (أسوشيتد بريس) -- Immunomedics المحدودة. قالَ الثّلاثاءُ biopharmaceutical شركة إستلمتْ a براءة إختراع للمرشّحِ hPAM مُنتَجها 4 لمُعَالَجَة السرطانِ البنكرياسيِ.
--
والشارت من سنتين لم ينزل عن 2 دولار .
http://finance.yahoo.com/q/bc?s=IMMU&t=2y&l=on&z=m&q=c&c=
--
وللعلم قد أستثمرت في الشركة على المدى القصير والبعيد. والهدف عندي فوق 5$ .
بالتوفيق للجميع ....
ملاحظة: لم تلتزمي في وعدك في تغير الصورة وأعتقد هي سبب كل خسائرك جربي تغير الصورة يمكن يتغير حظك
al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
نزول خبر الخميسِ 18, 8:30 صباحا ان شاء الله له تأثير على حركة السهم
http://biz.yahoo.com/pz/071018/128983.html
http://biz.yahoo.com/pz/071018/128983.html
الجاسوسة
موقوف
- التسجيل
- 15 أكتوبر 2007
- المشاركات
- 134
قلعتي استاهل اللي يصيرلي
الطمع شين
ترا خانقتني العبرة وأبي أبجي
الشركة:- اخبارها ممتازة الان وفي المستقبل
موريس يَتأسّى، إن. جْي . (أسوشيتد بريس) -- Immunomedics المحدودة. قالَ الثّلاثاءُ biopharmaceutical شركة إستلمتْ a براءة إختراع للمرشّحِ hPAM مُنتَجها 4 لمُعَالَجَة السرطانِ البنكرياسيِ.
--
والشارت من سنتين لم ينزل عن 2 دولار .
http://finance.yahoo.com/q/bc?s=IMMU&t=2y&l=on&z=m&q=c&c=
--
وللعلم قد أستثمرت في الشركة على المدى القصير والبعيد. والهدف عندي فوق 5$ .
بالتوفيق للجميع ....
ملاحظة: لم تلتزمي في وعدك في تغير الصورة وأعتقد هي سبب كل خسائرك جربي تغير الصورة يمكن يتغير حظك
وصل 1،92 يالحبيب
al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
abooyaser
عضو محترف - مشرف القسم السعودي
- التسجيل
- 24 مايو 2004
- المشاركات
- 3,425
Immunomedics Develops Two New Drug Immunoconjugates For Targeted Therapy of Colon and Lung Cancers
Thursday October 25, 3:43 pm ET
SAN FRANCISCO, Oct. 25, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of two new antibody-drug conjugates, potentially for the therapy of colon and lung cancers, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, in San Francisco, CA
The antibodies selected for this study were hMN-14, a non-internalizing humanized antibody that binds to the carcinoembryonic antigen (CEACAM5) expressed by many solid cancers, and hRS7, a rapidly internalizing humanized antibody targeting epithelial glycoprotein-1 (EGP-1) expressed in high amounts in certain human cancers. The Company has conducted clinical trials with naked and radiolabeled hMN-14 (labetuzumab) in patients with colorectal, breast and pancreas cancers
The drug selected for conjugation was SN-38, the active metabolite of irinotecan, a chemotherapeutic agent used for the treatment of colorectal, lung, and other cancers. SN-38 cannot be systemically administered to patients with cancer due to its toxicity and poor solubility. The two conjugated antibodies were designed to selectively deliver SN-38 to tumors, increasing the amount of drug reaching the tumors while minimizing the damage to other tissues and organs
In an animal model of colon cancer with lung metastases, therapy with labetuzumab-SN-38 increased median survival time 2-fold to 73.5 days compared to non-treated and non-targeting conjugate controls. Moreover, in another colon cancer model, 80% of treated animals (4/5) remained alive after 127 days, with 2 animals having no measurable tumors, while untreated animals were sacrificed by day 21 due to tumor burden. Similar results were observed in animals bearing human non-small-cell lung cancer treated with hRS7-SN-38. In this experiment, four out of five treated animals were tumor-free 118 days after receiving injections of human non-small-cell lung cancer cells
``These important preclinical studies demonstrate our ability to conjugate powerful drugs to two different humanized antibodies in a stable, predictable manner, while utilizing the same drug conjugation process. Our conjugation technology allows for the use of extremely potent drugs because they are selectively and stably delivered via the antibody,'' commented Cynthia L. Sullivan, President and Chief Executive Officer. ``For fiscal year 2008, we intend to further develop the labetuzumab-SN-38 conjugate as a potential therapeutic for lung, breast and colorectal cancers,'' she added
خبر نزل امس يمكن يحرك السهم من وقف الخساره 2.54 السعر حاليا 2.5
قولوا يارب
وتحسبا لأي طارئ واضع طلب علي 1. بكامل السيوله الإحتياط
سلالالالالالالالالالالالام
Thursday October 25, 3:43 pm ET
SAN FRANCISCO, Oct. 25, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of two new antibody-drug conjugates, potentially for the therapy of colon and lung cancers, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, in San Francisco, CA
The antibodies selected for this study were hMN-14, a non-internalizing humanized antibody that binds to the carcinoembryonic antigen (CEACAM5) expressed by many solid cancers, and hRS7, a rapidly internalizing humanized antibody targeting epithelial glycoprotein-1 (EGP-1) expressed in high amounts in certain human cancers. The Company has conducted clinical trials with naked and radiolabeled hMN-14 (labetuzumab) in patients with colorectal, breast and pancreas cancers
The drug selected for conjugation was SN-38, the active metabolite of irinotecan, a chemotherapeutic agent used for the treatment of colorectal, lung, and other cancers. SN-38 cannot be systemically administered to patients with cancer due to its toxicity and poor solubility. The two conjugated antibodies were designed to selectively deliver SN-38 to tumors, increasing the amount of drug reaching the tumors while minimizing the damage to other tissues and organs
In an animal model of colon cancer with lung metastases, therapy with labetuzumab-SN-38 increased median survival time 2-fold to 73.5 days compared to non-treated and non-targeting conjugate controls. Moreover, in another colon cancer model, 80% of treated animals (4/5) remained alive after 127 days, with 2 animals having no measurable tumors, while untreated animals were sacrificed by day 21 due to tumor burden. Similar results were observed in animals bearing human non-small-cell lung cancer treated with hRS7-SN-38. In this experiment, four out of five treated animals were tumor-free 118 days after receiving injections of human non-small-cell lung cancer cells
``These important preclinical studies demonstrate our ability to conjugate powerful drugs to two different humanized antibodies in a stable, predictable manner, while utilizing the same drug conjugation process. Our conjugation technology allows for the use of extremely potent drugs because they are selectively and stably delivered via the antibody,'' commented Cynthia L. Sullivan, President and Chief Executive Officer. ``For fiscal year 2008, we intend to further develop the labetuzumab-SN-38 conjugate as a potential therapeutic for lung, breast and colorectal cancers,'' she added
خبر نزل امس يمكن يحرك السهم من وقف الخساره 2.54 السعر حاليا 2.5
قولوا يارب
وتحسبا لأي طارئ واضع طلب علي 1. بكامل السيوله الإحتياط
سلالالالالالالالالالالالام
abooyaser
عضو محترف - مشرف القسم السعودي
- التسجيل
- 24 مايو 2004
- المشاركات
- 3,425
ياني صابر علي هذا السهم --- صبر ايووووووووووب --- هل سيخترق 3.54 --اليكم التشارت
الملفات المرفقه:
مستثمراون لاين
عضو نشط
abooyaser
عضو محترف - مشرف القسم السعودي
- التسجيل
- 24 مايو 2004
- المشاركات
- 3,425
نقول ان شاء الله يطوف السهم ال 3.5 ويبدع كما هو متوقع له
شكرا علي المرور والتعليق المتميز
حياااااااااااااك الله
سلالالالالالالالالالالالالام
دورة المؤشرنت للتحليل الفني
50 دينار كويتي